How soon will Wegovy start working — and what should you notice first?

What does 'working' actually feel like in the first few weeks?

The question our prescribers hear most often from people starting Wegovy is some version of: "I've done my first injection — when will I notice something?" The honest answer is that the first signal is rarely the number on the scales. Semaglutide acts on GLP-1 receptors in the brain and gut, slowing how fast food leaves your stomach and dampening the hunger signals that drive overeating. That process starts after your very first dose.

In the early days, people most often describe a quieter relationship with food: portions feel like enough, the urge to snack fades, or they simply stop thinking about their next meal as much. Some notice mild nausea or a feeling of fullness that arrives faster than usual, those early side effects are, in a way, confirmation that the medicine is active. The Wegovy overview at nume covers the side-effect profile in more detail if you want to know what's common versus what needs attention.

Actual weight loss in week one or two is usually small, sometimes a kilogram or less. If you're curious about how soon Wegovy starts working and what to realistically expect in those opening weeks, we cover that in detail separately. Bodies adjust to caloric reduction gradually, and water weight shifts can mask or exaggerate what's happening on fat tissue. Patience in the first month is genuinely warranted, not just a polite way of managing expectations.

Why does progress speed up over the titration schedule?

Wegovy is started at a low dose, 0.25mg weekly, and stepped up roughly every four weeks through 0.5mg, 1mg, and 1.7mg before reaching the 2.4mg maintenance dose. This isn't just caution about side effects, though it is that too. Each increase tends to bring a renewed appetite-suppressing effect, so the months around dose increases often feel like a second (or third) wave of progress.

By around weeks eight to twelve, most people on a stable dose have settled into a rhythm: eating less, moving more comfortably, and seeing a consistent trend on the scales. The STEP 1 trial, whose findings are summarised in the NHS patient information on semaglutide, showed average weight reduction of around 15% over 68 weeks, but the curve of loss is not a straight line. It steepens as the dose climbs and then levels off as the body reaches a new equilibrium. People who track their weight weekly often feel frustrated in months two and three; those who track monthly tend to feel encouraged.

The maximum licensed dose available in the UK is now 7.2mg, following MHRA approval in 2026 of a dedicated single-dose pen. Early data suggest average losses approaching those seen with tirzepatide at higher doses. Your prescriber decides which dose is appropriate and when to progress, that judgement is clinical, not automatic.

What if you're four weeks in and nothing seems to have changed?

A small number of people genuinely don't notice much in the first four weeks, and that's not necessarily a sign the treatment isn't working. The starter dose is calibrated for tolerability, not maximum effect. If you're well into your titration and still seeing no change in appetite or weight, the right step is to tell your prescribing team, not to adjust your dose yourself or stop the medicine.

Factors that can slow early progress include not yet being on an effective dose, dietary habits that haven't yet shifted with the reduced appetite cues, or underlying health conditions. Our semaglutide information page outlines the clinical context, and you can also explore weight-loss treatment options more broadly if you're considering whether Wegovy is the right fit. For specific concerns about your own treatment, our aftercare team is available seven days a week.

If you're looking at the cost of private treatment alongside all of this, our page on where to get Wegovy in the UK covers what a legitimate prescription service should include, and what to watch out for from sellers who cut corners on clinical oversight.

How does this compare to what the clinical evidence actually shows?

The STEP 1 trial ran for 68 weeks and enrolled adults with obesity or overweight plus at least one weight-related condition, without type 2 diabetes. Participants using semaglutide 2.4mg alongside a reduced-calorie diet and activity support lost an average of around 15% of their body weight. That's a meaningful average, but averages hide a wide spread. Some participants lost considerably more; some less. NICE's appraisal of semaglutide for weight management (TA875) drew on this and related evidence when recommending it for NHS use within specialist weight management services.

The trial also showed that weight loss continued to accumulate for most participants well into the second half of the study, reinforcing why early weeks are not the best moment to judge the medicine's effect. If you want a clearer sense of when Wegovy will start working for you personally, including the factors that influence your individual timeline, our dedicated page works through that in depth. The full picture emerges over months, not days.

Wegovy is a prescription-only medicine. A GPhC-registered independent prescriber (a named clinician, not an algorithm) reviews every consultation at nume before any treatment is approved. For those who also want to understand the Wegovy vidal summary, covering licensed indications, dosing and pharmacological detail, that information is available separately. If you'd like to understand whether semaglutide is clinically appropriate for you, starting a free consultation is the right first step.